Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) Operating Expenses (2018 - 2025)

Volitionrx filings provide 9 years of Operating Expenses readings, the most recent being $5.3 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 11.85% to $5.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.5 million, a 16.96% decrease, with the full-year FY2025 number at $23.5 million, down 16.96% from a year prior.
  • Operating Expenses hit $5.3 million in Q4 2025 for Volitionrx, down from $5.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $9.8 million in Q2 2023 to a low of $5.3 million in Q4 2025.
  • Median Operating Expenses over the past 5 years was $7.7 million (2021), compared with a mean of $7.4 million.
  • Biggest five-year swings in Operating Expenses: surged 68.43% in 2021 and later plummeted 33.52% in 2024.
  • Volitionrx's Operating Expenses stood at $8.8 million in 2021, then fell by 7.6% to $8.1 million in 2022, then rose by 10.51% to $9.0 million in 2023, then plummeted by 33.52% to $6.0 million in 2024, then decreased by 11.85% to $5.3 million in 2025.
  • The last three reported values for Operating Expenses were $5.3 million (Q4 2025), $5.7 million (Q3 2025), and $6.7 million (Q2 2025) per Business Quant data.